Patents Assigned to Connaught Laboratories Limited
  • Patent number: 7118749
    Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.
    Type: Grant
    Filed: January 14, 2002
    Date of Patent: October 10, 2006
    Assignee: Connaught Laboratories Limited
    Inventors: Sheena M. Loosmore, Robin E. Harkness, Anthony B. Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew D. Murdin, Michel H. Klein
  • Patent number: 6403101
    Abstract: In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding a lorf2 protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the lorf2 gene in the host. Modifications are possible within the scope of this invention.
    Type: Grant
    Filed: October 26, 1999
    Date of Patent: June 11, 2002
    Assignee: Connaught Laboratories Limited
    Inventors: Andrew D. Murdin, Raymond P. Oomen, Pamela L. Dunn
  • Patent number: 6403102
    Abstract: In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding an PilG-like protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the PilG-like gene in the host. Modifications are possible within the scope of this invention.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: June 11, 2002
    Assignee: Connaught Laboratories Limited
    Inventors: Andrew D. Murdin, Raymond P. Oomen, Pamela L. Dunn
  • Publication number: 20010051163
    Abstract: Pertactin (formerly 69 kDa protein) is recovered in stable biologically pure form having no detectable adenylate cyclase activity from fermentation broth from the fermentation of Bordetella pertussis as well as from the cells. The broth is processed to selectively remove pertussis toxin (PT) and filamentous haemagglutinin (FHA), the pertactin is precipitated by ammonium sulphate and the precipitate is dissolved in buffer at pH 6.0 to 8.5, the solution then is passed through hydroxyapatite and Q-Sepharose® chromatograph columns before final ultrafiltration. Cells are extracted with urea and the extract ultrafiltered and diafiltered. The pertactin is precipitated from the extract and the precipitate processed as above. In a variation, the broth is contacted with ammonium sulphate to precipitate pertactin, PT and FHA, the precipitate is dissolved and the PT and FHA selectively removed, before the solution is passed to the chromatograph columns.
    Type: Application
    Filed: June 25, 2001
    Publication date: December 13, 2001
    Applicant: Connaught Laboratories Limited
    Inventors: Gail Jackson, Raafat Fahim, Larry Tan, Pele Chong, John Voss, Michel Klein
  • Patent number: 6306637
    Abstract: Immunogenic envelope glycoproteins are produced from enveloped virus, such as of the paramyxoviridae family, particularly PIV-3 and RSV, by culturing the virus in the substantial absence of exogenous serum proteins, isolating the virus from the tissue culture, solubilizing the envelope glycoproteins and isolating the solubilized envelope glycoproteins by chromatography.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 23, 2001
    Assignee: Connaught Laboratories Limited
    Inventors: Mary Elizabeth Ewasyshyn, Barry Ian Caplan, Anne-Marie Bonneau, Michel Henri Klein
  • Patent number: 6291157
    Abstract: Non-infectious, retrovirus-like particles comprise an assembly of an env gene product, a pol gene product and a gag gene product contain an antigenic marker which is non-retroviral or non-HIV retroviral. In one embodiment, the marker comprises an amino acid sequence containing an epitope inserted into the gag gene product at an antigenically-active insertion site. In another embodiment, the marker comprises an antigenic anchor sequence operatively connected to the env gene product replacing endogenous anchoring function. The corresponding nucleic acid molecules are described. The non-infectious, retrovirus-like particles have utility in in vivo administration including to humans and in diagnosis. The presence of the antigenic marker enables recognition that antiserum containing anti-retroviral antibodies has been generated by exposure to the non-infectious retrovirus-like particles by testing for antibodies specific to the antigenic marker.
    Type: Grant
    Filed: February 23, 1998
    Date of Patent: September 18, 2001
    Assignee: Connaught Laboratories Limited
    Inventors: Benjamin Rovinski, Shi-Xian Cao, Fei-Long Yao, Roy Persson, Michel H. Klein
  • Patent number: 6262016
    Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.
    Type: Grant
    Filed: July 21, 1997
    Date of Patent: July 17, 2001
    Assignee: Connaught Laboratories Limited
    Inventors: Sheena Loosmore, Robin Harkness, Anthony Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew Murdin, Michel Klein
  • Patent number: 6245549
    Abstract: Immunogenic envelope glycoproteins are produced from enveloped virus, such as of the paramyxoviridae family, particularly PIV-3 and RSV, by culturing the virus in the substantial absence of exogenous serum proteins, isolating the virus from the tissue culture, solubilizing the envelope glycoproteins and isolating the solubilized envelope glycoproteins by chromatography.
    Type: Grant
    Filed: November 25, 1991
    Date of Patent: June 12, 2001
    Assignee: Connaught Laboratories Limited
    Inventors: Mary Elizabeth Ewasyshyn, Barry Ian Caplan, Anne-Marie Bonneau, Michel Henri Klein
  • Patent number: 6235523
    Abstract: Vectors for DNA immunization against cervical cancer comprise a nucleic acid molecule encoding at least one non-toxic T-cell epitope of the E6 and/or E7 antigens of a strain of human papilloma virus (HPV) associated with cervical cancer, such as HPV-16, and a promoter operatively coupled to the nucleic acid molecule for expression of the nucleic acid molecule in a host to which the vector is administered.
    Type: Grant
    Filed: September 3, 1999
    Date of Patent: May 22, 2001
    Assignee: Connaught Laboratories Limited
    Inventors: Diane M. Gajewczyk, Roy Persson, Fei-Long Yao, Shi-Xian Cao, Michel H. Klein, James Tartaglia, Phillipe Moingeon, Benjamin Rovinski
  • Patent number: 6228423
    Abstract: Copolymers designed for use as particulate carriers containing functionalizable amino acid subunits for coupling with targeting ligand are described. The copolymers are polyesters composed of &agr;-hydroxy acid subunits such as D,L-lactide and &agr;-amino acid subunits such as serine or in the preferred embodiment, terpolymers of D,L-lactide and glycolide and &agr;-amino acid subunits such as serine. Stable vaccine preparations useful as delayed release formulations containing antigen(s) or antigen(s) and co-adjuvants encapsulated within or physically mixed with polymeric microparticles are described. The particulate carriers are useful for delivering agents to the immune system of a subject by mucosal or parenteral routes to produce immune responses, including antibody responses.
    Type: Grant
    Filed: February 11, 2000
    Date of Patent: May 8, 2001
    Assignee: Connaught Laboratories Limited
    Inventors: Kenneth K. Sokoll, Pele Chong, Michel H. Klein
  • Patent number: 6225091
    Abstract: Multimeric hybrid genes encoding the corresponding chimeric protein comprise a gene sequence coding for an antigenic region of a protein from a first pathogen linked to a gene sequence coding for an antigenic region of a protein from a second pathogen. The pathogens particularly are parainfluenza virus (PIV) and respiratory syncytial virus (RSV). A single recombinant immunogen is capable of protecting infants and similar susceptible individuals against diseases caused by both PIV and RSV.
    Type: Grant
    Filed: January 6, 1993
    Date of Patent: May 1, 2001
    Assignee: Connaught Laboratories Limited
    Inventors: Michel H. Klein, Run-Pan Du, Mary E. Ewasyshyn
  • Patent number: 6224881
    Abstract: The present invention relates to a DNA molecule conferring on Mycobacterium tuberculosis an ability to enter mammalian cells and to survive within macrophages. Peptides, proteins, or polypeptides (e.g. the Mycobacterium cell entry protein or Mcep) encoded by this gene fragment are useful in vaccines to prevent infection by Mycobacterium tuberculosis, while the antibodies raised against these peptides, proteins, or polypeptides can be employed in passively immunizing those already infected by the organism. These proteins, peptides, polypeptides, and antibodies may be utilized in diagnostic assays to detect Mycobacterium tuberculosis in tissue or bodily fluids. The peptides, proteins, or polypeptides of the present invention can be associated with various other therapeutic materials, for administration to mammals, particularly humans, to achieve uptake of those materials by such cells.
    Type: Grant
    Filed: August 7, 1996
    Date of Patent: May 1, 2001
    Assignees: Cornell Research Foundation, Inc., Connaught Laboratories Limited
    Inventors: Lee W. Riley, Pele Chong
  • Patent number: 6211343
    Abstract: An isolated and purified lactoferrin receptor protein is isolated and purified from bacterial pathogens, including Moraxella and Neisseria, and has a molecular weight of between about 70,000 and about 90,000, as determined by SDS-PAGE. Such lactoferrin receptor protein may be provided in combination with a lactoferrin receptor protein from the bacterial pathogen of a molecular weight of about 100,000 to about 105,000 daltons. The lactoferrin receptor protein may be produced by providing a solubilized membrane preparation from the bacterial pathogen containing lactoferrin receptor proteins, non-lactoferrin receptor proteins and other contaminants, complexing the lactoferrin receptor proteins with lactoferrin and purifying the resulting complexes substantially free from the non-lactoferrin receptor proteins and the other contaminants, and separating the novel lactoferrin receptor protein from the complexes.
    Type: Grant
    Filed: August 10, 1999
    Date of Patent: April 3, 2001
    Assignee: Connaught Laboratories Limited
    Inventors: Anthony B. Schryvers, Robert A. Bonnah
  • Patent number: 6190668
    Abstract: An isolated and purified non-denatured transferrin receptor protein of a Moraxella strain, particularly M. catarrhalis, has an apparent molecular mass of about 80 to about 90 kDa, as determined by SDS-PAGE. The transferrin receptor protein or a fragment analog thereof is useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a strain of Moraxella. The transferrin receptor protein is isolated from strains of Moraxella catarrhalis by a procedure including extraction of agent soluble proteins of a cell mass produced by cultivating the strain under iron-starved conditions. The transferrin receptor protein is selectively solubilized from the extracted cell mass and purified.
    Type: Grant
    Filed: July 30, 1998
    Date of Patent: February 20, 2001
    Assignee: Connaught Laboratories Limited
    Inventors: Yan-Ping Yang, Lisa E. Myers, Robin E. Harkness, Michel H. Klein
  • Patent number: 6184371
    Abstract: Purified and isolated nucleic acid molecules are provided which encode lactoferrin receptor proteins of Moraxella, such as M. catarrhalis, or a fragment or an analog of the lactoferrin receptor protein. The nucleic acid sequence may be used to produce recombinant lactoferrin receptor proteins Lbp1, Lbp2 and ORF3 of the strain of Moraxella free of other proteins of the Moraxella strain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection.
    Type: Grant
    Filed: May 8, 1998
    Date of Patent: February 6, 2001
    Assignee: Connaught Laboratories Limited
    Inventors: Sheena M. Loosmore, Run-Pan Du, Quijun Wang, Yan-Ping Yang, Michel H. Klein
  • Patent number: 6180758
    Abstract: Synthetic peptides have an amino acids sequence corresponding to at least one antigenic determinant of at least one protein, usually a structural protein, particularly the E1, E2 or C proteins, of rubella virus (RV), are used as is, in hybrid or chimeric tandem T-B form, in lipidated form, linked to a carrier molecule and/or polymerized to form molecular aggregates, in vaccines against rubella. Analogs of peptides which are human T-cell determinants are used to treat rubella-associated autoimmune disorders.
    Type: Grant
    Filed: April 14, 1997
    Date of Patent: January 30, 2001
    Assignee: Connaught Laboratories Limited
    Inventors: Pele Chong, Shirley Gillam, Dawei Ou, Aubrey Tingle
  • Patent number: 6180398
    Abstract: An immunization strategy to provide protection against disease caused by infection with a paramyxoviridae virus, specifically respiratory syncytial virus (RSV) and parainfluenza virus, is described. A priming intranasal administration of a recombinant virus expressing at least one RSV or PIV protein or immunogenic sequence there first is made to the host followed by a booster administration of at least one purified RSV or PIV protein or immunogenic fragment thereof, which may be adjuvanted with alum. This immunization strategy provides a safe and effective means of controlling RSV and PIV infections. The strategy leads to a stronger protective immune response than other strategies and to the induction of a more balanced Th-1/Th-2 type response than previously attained.
    Type: Grant
    Filed: July 12, 1996
    Date of Patent: January 30, 2001
    Assignees: Virogeneitics Corporation, Connaught Laboratories Limited
    Inventors: Michel H. Klein, James Tartaglia, George A. Cates, Mary E. Ewasyshyn
  • Patent number: 6177085
    Abstract: Immunogenic conjugate molecules comprising at least a portion of a capsular polysaccharide of a Streptococcus strain linked to at least a portion of an outer membrane protein of a Haemophilus strain are provided in which the immunogenicity of the capsular polysaccharide is increased. Particularly capsular polysaccharide from Streptococcus pneumoniae are linked to an outer membrane protein of a Haemophilus influenzae strain, which protein may be the P1, P2 or particularly the P6 outer membrane protein. Conjugate molecules comprising the P6 protein linked to a capsular polysaccharide from an encapsulated pathogen other than Streptococcus also are described, in which the immunogenicity of the capsular polysaccharide is enhanced. Such conjugate molecules may be incorporated into immunogenic compositions for protecting a host against disease caused by the Streptococcus strain and preferably also the Haemophilus strain.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 23, 2001
    Assignee: Connaught Laboratories Limited
    Inventors: Yan-ping Yang, Ali Kandil, Lucy Gisonni, Raafat Emil Fahmy Fahim, Michel Henri Klein
  • Patent number: 6171783
    Abstract: Multimeric hybrid genes encoding the corresponding chimeric protein comprise a gene sequence coding for an antigenic region of a protein from a first pathogen linked to a gene sequence coding for an antigenic region of a protein from a second pathogen. The pathogens particularly are parainfluenza virus (PIV) and respiratory syncytial virus (RSV). A single recombinant immunogen is capable of protecting infants and similar susceptible individuals against diseases caused by both PIV and RSV.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 9, 2001
    Assignee: Connaught Laboratories Limited
    Inventors: Michel H. Klein, Run-Pan Du, Mary E. Ewasyshyn
  • Patent number: 6168928
    Abstract: The three-dimensional structure of crystalline pertussis holotoxin (PT) has been determined by X-ray crystallography. Crystal structures have also been determined for complexes of pertussis toxin with molecules relevant to the biological activity of PT. These three-dimensional structures were analyzed to identify functional amino acids appropriate for modification to alter the biological properties of PT. Similar procedures may be used to predict amino acids which contribute to the toxicity of the holotoxin, to produce immunoprotective, genetically-detoxified analogs of pertussis toxin.
    Type: Grant
    Filed: May 21, 1998
    Date of Patent: January 2, 2001
    Assignee: Connaught Laboratories Limited
    Inventors: Randy J. Read, Penelope E. Stein, Stephen A. Cockle, Raymond P. Oomen, Sheena Loosmore, Michel H. Klein, Glen D. Armstrong, Bart Hazes